← Back to Search

SGLT2 Inhibitor

Dapagliflozin for Cardiovascular Risk (DAPA-SWEET Trial)

Phase 2
Recruiting
Led By David ZI Cherney, MD PhD FRCPC
Research Sponsored by University Health Network, Toronto
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
Awards & highlights

DAPA-SWEET Trial Summary

This trial looks at how a diabetes medication affects various aspects of heart and kidney health in people with and without diabetes.

DAPA-SWEET Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks)
This trial's timeline: 3 weeks for screening, Varies for treatment, and outcome will remeasured at 2 time points: acute (1 week) and chronic (12 weeks) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Arterial stiffness
Secondary outcome measures
Bioimpedence spectroscopy
Diastolic blood pressure
Echocardiography
+25 more
Other outcome measures
Drug related adverse events
Number of hypoglycaemic episodes
Serious adverse events

Side effects data

From 2023 Phase 3 trial • 240 Patients • NCT04298229
8%
Hypoglycemia
7%
HF exacerbation
4%
Death
1%
Severe Hypotension
1%
Acute Kidney Injury
100%
80%
60%
40%
20%
0%
Study treatment Arm
Structured Usual Care
Dapagliflozin + Structured Usual Care

DAPA-SWEET Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Dapagliflozin Treatment ArmExperimental Treatment1 Intervention
Dapagliflozin Tablets Total Dose 10mg daily for 12 weeks
Group II: Placebo ArmPlacebo Group1 Intervention
Placebo Matching Dapagliflozin Tablet for 12 weeks
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Dapagliflozin
FDA approved

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreOTHER
656 Previous Clinical Trials
1,550,572 Total Patients Enrolled
MOUNT SINAI HOSPITALOTHER
40 Previous Clinical Trials
14,581 Total Patients Enrolled
University Health Network, TorontoLead Sponsor
1,468 Previous Clinical Trials
484,469 Total Patients Enrolled

Media Library

Dapagliflozin 10 MG (SGLT2 Inhibitor) Clinical Trial Eligibility Overview. Trial Name: NCT04258371 — Phase 2
Cardiovascular Risk Research Study Groups: Placebo Arm, Dapagliflozin Treatment Arm
Cardiovascular Risk Clinical Trial 2023: Dapagliflozin 10 MG Highlights & Side Effects. Trial Name: NCT04258371 — Phase 2
Dapagliflozin 10 MG (SGLT2 Inhibitor) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04258371 — Phase 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Recent research and studies
clinicaltrials.govStudy
DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk
David Z.I. Cherney 2020. "DAPAgliflozin Sodium Water glucosE EffecTs in Patients at High Cardiovascular Risk". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04258371.
All > Cardiovascular
~10 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top